Lineage Cell Therapeutics reported that the company's proprietary AlloSCOPE platform ? Allogeneic, Scalable, Consistent, Off-the-shelf, Pluripotent Cell Engineering ? enables the manufacture of millions of doses of cell-based products derived from a single initial cell line.
In its January 2026 shareholder letter, Lineage disclosed it is now evaluating AlloSCOPE as a solution to the massive production scale required for commercially-viable islet cell therapy in Type 1 Diabetes ? a program that runs thematically parallel to Avaí Bio's own diabetes and anti-aging efforts through encapsulated cells. Lineage also achieved a first milestone under its worldwide collaboration with Roche's Genentech for OpRegen, an allogeneic retinal pigment epithelium cell therapy being developed for geographic atrophy secondary to age-related macular degeneration.
Together with new corneal endothelial (COR1) and additional undisclosed cell programs, Lineage's expanding pipeline illustrates how cell-based regenerative platforms are being repositioned from niche indications toward broader applications in age-related disease.
